AGEN Quote, Financials, Valuation and Earnings

Kura Oncology has a net margin of -170.88% compared to Agenus's net margin of -35.66%. Agenus's return on equity of -- beat Kura Oncology's return on equity of --.

Agenus has a consensus price target of $7.00, signalling upside risk potential of 311.77%. On the other hand Kura Oncology has an analysts' consensus of $28.00 which suggests that it could grow by 385.27%. Given that Kura Oncology has higher upside potential than Agenus, analysts believe Kura Oncology is more attractive than Agenus.

Agenus has a beta of 1.578, which suggesting that the stock is 57.761% more volatile than S&P 500. In comparison Kura Oncology has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.274%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kura Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Kura Oncology pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are smaller than Kura Oncology quarterly revenues of $53.9M. Agenus's net income of -$45.9M is lower than Kura Oncology's net income of -$19.2M. Notably, Agenus's price-to-earnings ratio is -- while Kura Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.27x versus -- for Kura Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -170.88% compared to Agenus's net margin of -2.16%. Agenus's return on equity of -- beat Myomo's return on equity of -48.64%.

Agenus has a consensus price target of $7.00, signalling upside risk potential of 311.77%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 108.8%. Given that Agenus has higher upside potential than Myomo, analysts believe Agenus is more attractive than Myomo.

Agenus has a beta of 1.578, which suggesting that the stock is 57.761% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Myomo quarterly revenues of $12.1M. Agenus's net income of -$45.9M is lower than Myomo's net income of -$260.1K. Notably, Agenus's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.27x versus 5.14x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -170.88% compared to Agenus's net margin of -63.22%. Agenus's return on equity of -- beat Nuwellis's return on equity of -800.59%.

Agenus has a consensus price target of $7.00, signalling upside risk potential of 311.77%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1295.12%. Given that Nuwellis has higher upside potential than Agenus, analysts believe Nuwellis is more attractive than Agenus.

Agenus has a beta of 1.578, which suggesting that the stock is 57.761% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.510, suggesting its less volatile than the S&P 500 by 49.013%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Nuwellis quarterly revenues of $2.3M. Agenus's net income of -$45.9M is lower than Nuwellis's net income of -$1.5M. Notably, Agenus's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.27x versus 0.17x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -170.88% compared to Agenus's net margin of 35.65%. Agenus's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Agenus has a consensus price target of $7.00, signalling upside risk potential of 311.77%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 501.66%. Given that Protalix BioTherapeutics has higher upside potential than Agenus, analysts believe Protalix BioTherapeutics is more attractive than Agenus.

Agenus has a beta of 1.578, which suggesting that the stock is 57.761% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Protalix BioTherapeutics quarterly revenues of $18.2M. Agenus's net income of -$45.9M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Agenus's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 80.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.27x versus 3.74x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.